Entest Biomedical, Inc. CEO to Interview Noted Stem Cell Transplant Physician Dr. Ewa Carrier on Advances in Stem Cell Therapy

SAN DIEGO, CA--(Marketwire - March 26, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) announced today that Chairman & CEO David Koos will interview noted stem cell transplant physician Dr. Ewa Carrier on the Company’s weekly blogcast Wednesday, March 31, 2010 at 11:00 a.m. PST. Dr. Carrier is an internationally recognized expert in stem cell transplantation and a member of Entest’s Scientific Advisory Board.

Topics to be covered in the interview will include the role of stem cells in treating cancer, advances in heart and lung treatment with stem cell therapy and the use of stem cells in creating blood for transfusion from stem cells.

Entest’s Chairman & CEO David Koos stated, “We are extremely fortunate to have Dr. Carrier on our Scientific Advisory Board. Her knowledge in stem cell therapy applications is of great significance to Entest as the Company moves forward.”

The blogcast can be accessed at Company’s blog site: www.entestbioblog.com/live Wednesday March 31, 2010 at 11:00 am PST.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest Biomedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.